

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 27 February 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023.

Under the programme initiated 1 February 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.6 billion in the period from 1 February 2023 to 2 May 2023.

Since the announcement of the programme, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,044,072		1,002,446,653
16 February 2023	93,000	973.30	90,516,454
17 February 2023	93,000	978.80	91,028,429
20 February 2023	91,000	983.84	89,529,530
21 February 2023	91,000	993.62	90,419,460
22 February 2023	90,800	997.29	90,554,173
23 February 2023	89,500	1,001.56	89,639,529
24 February 2023	90,330	996.63	90,026,008
Accumulated under the programme	1,682,702		1,634,160,237

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 28,829,028 B shares of DKK 0.20 as treasury shares, corresponding to 1.3% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 28 billion during a 12-month period beginning 1 February 2023. As of 24 February 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 1,682,702 B shares at an average share price of DKK 971.15 per B share equal to a transaction value of DKK 1,634,160,237.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#) and [YouTube](#).

Contact for further information

Media:

Ambre Brown Morley

+45 3079 9289

abmo@novonordisk.com

Natalia Salomao Abrahao (US)

+1 848 304 1027

niaa@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com